4582 — SymBio Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapSucker Stock

Annual income statement for SymBio Pharmaceuticals, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	JAS	JAS	JAS	JAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	8,257	10,008	5,590	2,453	1,308
Cost of Revenue
Gross Profit	5,800	7,600	4,411	1,873	947
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	7,241	7,938	6,894	6,447	5,849
Operating Profit	1,016	2,070	-1,304	-3,994	-4,541
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,001	2,106	-1,195	-3,807	-4,749
Provision for Income Taxes
Net Income After Taxes	2,032	1,179	-1,963	-3,833	-4,776
Net Income Before Extraordinary Items
Net Income	2,032	1,179	-1,963	-3,833	-4,776
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2,032	1,179	-1,963	-3,833	-4,776
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	52.3	28.3	-41.2	-83.3	-93.8
Dividends per Share